Determinants of circulating calcitriol in cardiovascular disease

被引:2
|
作者
Zittermann, A. [1 ]
Zelzer, S. [2 ]
Herrmann, M. [2 ]
Gummert, J. F. [1 ]
Kleber, M. [3 ,4 ]
Trummer, C. [5 ]
Theiler-Schwetz, V. [5 ]
Keppel, M. H. [2 ]
Maerz, W. [3 ,4 ,6 ]
Pilz, S. [5 ]
机构
[1] Herz & Diabeteszentrum NRW, Clin Thorac & Cardiovasc Surg, Georgstr 11, D-32545 Bad Oeynhausen, Germany
[2] Med Univ Graz, Clin Inst, Med & Chem Lab Diagnost, A-8036 Graz, Austria
[3] Heidelberg Univ, Med Fac Mannheim, Dept Med Nephrol Hypertensiol Rheumatol Endocrinol, D-68167 Mannheim, Germany
[4] SYNLAB MVZ Humangenet Mannheim, D-68163 Mannheim, Germany
[5] Med Univ Graz, Dept Internal Med, Div Endocrinol & Diabetol, A-8036 Graz, Austria
[6] Deutschland GmbH, SYNLAB Holding, D-68159 Augsburg, Germany
关键词
Calcitriol; Fibroblast growth factor-23; 25-hydroxyvitamin D; Cardiovascular disease; Regulation; GROWTH-FACTOR; 23; CHRONIC KIDNEY-DISEASE; VITAMIN-D LEVELS; VASCULAR CALCIFICATION; 25-HYDROXYVITAMIN D; 1,25-DIHYDROXYVITAMIN-D; METAANALYSIS; RISK; ASSOCIATION; MORTALITY;
D O I
10.1016/j.jsbmb.2024.106528
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Circulating calcitriol may contribute to the risk of cardiovascular disease (CVD), but its regulation in patients with CVD is poorly characterized. We therefore aimed to assess determinants of circulating calcitriol in these patients. We analyzed 2183 independent samples from a large cohort of patients scheduled for coronary angiography and 1727 independent samples from different other cohorts from patients with a wide range of CVDs, including heart transplant candidates, to quantify the association of different parameters with circulating calcitriol. We performed univariable and multivariable linear regression analyses using the mathematical function that fitted best with circulating calcitriol. In the multivariable analysis of the large single cohort, nine parameters remained significant, explaining 30.0 % (32.4 % after exclusion of 22 potential outliers) of the variation in circulating calcitriol (r=0.548). Log-transformed 25-hydroxyvitamin D [25(OH)D] and log-transformed glomerular filtration rate were the strongest predictors, explaining 17.6 % and 6.6 %, respectively, of the variation in calcitriol. In the analysis of the combined other cohorts, including heart transplant candidates, the multivariable model explained a total of 42.6 % (46.1 % after exclusion of 21 potential outliers) of the variation in calcitriol (r=0.653) with log-transformed fibroblast growth factor-23 and log-transformed 25(OH)D explaining 29.0 % and 6.2 %, respectively. Circulating 25(OH)D was positively and FGF-23 inversely associated with circulating calcitriol. Although significant, PTH was only a weak predictor of calcitriol in both analyses (<2.5 %). In patients with CVD, FGF-23 and 25(OH)D are important independent determinants of circulating calcitriol. The relative importance of these two parameters may vary according to CVD severity. Future studies should focus on the clinical importance of regulating circulating calcitriol by different parameters.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Circulating miRNAs: Reflecting or Affecting Cardiovascular Disease?
    van Empel, Vanessa P. M.
    De Windt, Leon J.
    Martins, Paula A. da Costa
    CURRENT HYPERTENSION REPORTS, 2012, 14 (06) : 498 - 509
  • [22] Circulating Sulfhydryl Oxidase and Risk of Cardiovascular Disease
    Qian, Juying
    Chen, Ao
    Chen, Zhangwei
    Ge, Junbo
    CIRCULATION, 2023, 148
  • [23] Circulating gamma glutamyltransferase and prediction of cardiovascular disease
    Kunutsor, Setor K.
    Bakker, Stephan J. L.
    Kootstra-Ros, Jenny E.
    Gansevoort, Ronald T.
    Dullaart, Robin P. F.
    ATHEROSCLEROSIS, 2015, 238 (02) : 356 - 364
  • [24] Circulating markers of endothelial function in cardiovascular disease
    Constans, Joel
    Conri, Claude
    CLINICA CHIMICA ACTA, 2006, 368 (1-2) : 33 - 47
  • [25] Candidate circulating biomarkers for the cardiovascular disease continuum
    Dotsenko, Olena
    Chackathayil, Julia
    Patel, Jeetesh V.
    Gill, Paramjit S.
    Lip, Gregory Y. H.
    CURRENT PHARMACEUTICAL DESIGN, 2008, 14 (24) : 2445 - 2461
  • [26] Circulating microparticles in cardiovascular disease: going on stage!
    Fernandez, Mauricio
    Calligaris, Sebastian D.
    BIOMARKERS, 2019, 24 (05) : 423 - 428
  • [27] Circulating Progenitor Cells and Childhood Cardiovascular Disease
    Eric J. Kort
    Lacey Croskey
    Taryn Scibienski
    Surender Rajasekaran
    Stefan Jovinge
    Pediatric Cardiology, 2016, 37 : 225 - 231
  • [28] Circulating miRNAs: messengers on the move in cardiovascular disease
    Egea, Virginia
    Schober, Andreas
    Weber, Christian
    THROMBOSIS AND HAEMOSTASIS, 2012, 108 (04) : 590 - 591
  • [29] Circulating Progenitor Cells and Childhood Cardiovascular Disease
    Kort, Eric J.
    Croskey, Lacey
    Scibienski, Taryn
    Rajasekaran, Surender
    Jovinge, Stefan
    PEDIATRIC CARDIOLOGY, 2016, 37 (02) : 225 - 231
  • [30] Sex Differences in Circulating Biomarkers of Cardiovascular Disease
    Lau, Emily S.
    Paniagua, Samantha M.
    Guseh, James Sawalla
    Bhambhani, Vijeta
    Zanni, Markella V.
    Courchesne, Paul
    Lyass, Asya
    Larson, Martin G.
    Levy, Daniel
    Ho, Jennifer E.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 74 (12) : 1543 - 1553